• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,204.00
  • 0.67 %
  • $54.73
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Halozyme Therapeutics, Inc. (HALO) Stock Price, News & Analysis

Halozyme Therapeutics, Inc. (HALO) Stock Price, News & Analysis

Currency in USD Disclaimer

$45.72

-$0.04

(-0.09%)

Day's range
$44.8
Day's range
$46.01
50-day range
$42.01
Day's range
$63.5
  • Country: US
  • ISIN: US40637H1095
52 wk range
$33.15
Day's range
$65.53
  • CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 4.15
  • Piotroski Score 8.00
  • Grade Buy
  • Symbol (HALO)
  • Company Halozyme Therapeutics, Inc.
  • Price $45.72
  • Changes Percentage (-0.09%)
  • Change -$0.04
  • Day Low $44.80
  • Day High $46.01
  • Year High $65.53

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/18/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $58.00
  • High Stock Price Target $65.00
  • Low Stock Price Target $44.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2.41
  • Trailing P/E Ratio 21.1
  • Forward P/E Ratio 21.1
  • P/E Growth 21.1
  • Net Income $281.59 M

Income Statement

Quarterly

Annual

Latest News of HALO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Halozyme Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of HALO in the last quarter?

    In the last quarter Halozyme Therapeutics, Inc. earnings were on Thursday, October, 31st. The Halozyme Therapeutics, Inc. maker reported $1.27 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.29.

  • What is the Halozyme Therapeutics, Inc. stock price today?

    Today's price of Halozyme Therapeutics, Inc. is $45.72 — it has decreased by -0.09% in the past 24 hours. Watch Halozyme Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Halozyme Therapeutics, Inc. release reports?

    Yes, you can track Halozyme Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Halozyme Therapeutics, Inc. stock forecast?

    Watch the Halozyme Therapeutics, Inc. chart and read a more detailed Halozyme Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Halozyme Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Halozyme Therapeutics, Inc. stock ticker.

  • How to buy Halozyme Therapeutics, Inc. stocks?

    Like other stocks, HALO shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Halozyme Therapeutics, Inc.'s EBITDA?

    Halozyme Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Halozyme Therapeutics, Inc.’s financial statements.

  • What is the Halozyme Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.3395754975, which equates to approximately 33.96%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Halozyme Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Halozyme Therapeutics, Inc.'s financials relevant news, and technical analysis. Halozyme Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Halozyme Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Halozyme Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Halozyme Therapeutics, Inc. for its last quarter?

    Halozyme Therapeutics, Inc. published it's last quarterly revenues at $290.08 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.